Skip to main content

Table 2 RNA measurements of latency reversal after presentation of the indicated antigens by dendritic cells for one of the participants shown in Fig. 4; cells were cultured with or without raltegravir

From: Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents

Assay DMSO α-CD3 +
α-CD28
CMV pp65 HIV-1 p55 Gag SIV p55 Gag CMV pp65 peptide poola CEFTb peptide pool HIV-1 Gag peptide pool
cfc-RNA raltegravird n.d.e (0) 24,000 (100) n.d. (0) 130 (0.5) n.d. (0) 107 (0.4) n.d. (0) 8300 (35)
cf-RNA
no raltegravirf
n.d. (0) 1.2 × 1010 (100) n.d. (0) 1 × 1010 (87) 370 (3 × 10− 6) 440 (4 × 10− 6) n.d. (0) 33,000 (2.7 × 10− 4)
cag-RNA
raltegravird
n.d. (0) 151 (100) 3 (2) n.d. (0) n.d. (0) 14 (9) 30 (20) 96 (64)
cag-RNA
no raltegravirf
n.d. (0) 1.2 × 109 (100) n.d. (0) 7.5 × 106 (0.63) n.d. (0) n.d. (0) n.d. (0) 50 (4 × 10− 6)
  1. Values in parentheses are the percent of the α-CD3/α-CD28 control
  2. aAll peptide pools were used at 1 µg/ml each peptide
  3. bCEFT, pool of MHC class-II restricted peptides from CMV, EBV, influenza virus, and tetanus toxoid
  4. ccf, cell-free, virion-associated RNA in copies/ml
  5. dRaltegravir was used at 1 µM to block viral propagation and the cells were stimulated for 7 days
  6. en.d., not detected
  7. fCells were stimulated for 18 days in the absence of raltegravir
  8. gca, cell-associated, Tat/Rev mRNA in copies/µg RNA
\